Program
vilobelimab
Also written as “IFX-1”, “Cohort A: vilobelimab” and “Vilobelimab”.
Its studies are mostly in Respiratory Distress Syndrome · Pyoderma Gangrenosum · Granulomatosis with Polyangiitis · Hidradenitis Suppurativa · Neoplasm Metastasis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| InflaRx | 110 open or running | phase 3since Apr 1, 2020 | Mar 18, 2011 | none ahead |
| PPD Development, LP | 22 open or running | phase 2since Nov 20, 2024 | Nov 20, 2024 | Jul 2028phase 2 · NCT06703073 |
Also a collaborator on its studies: edesa-biotech-inc, Hoffmann-La Roche, Merck, iqvia-pty-ltd and quintiles-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 18, 2011First study: phase 1 study in SepsisNew to InflaRxInflaRx · NCT01319903 · 26 enrolled · Germany
- Sep 18, 2014Phase 2 study in SepsisInflaRx · NCT02246595 · 72 enrolled · Germany
- Jun 17, 2016Phase 2 study in Systemic Inflammatory Response SyndromeInflaRx · NCT02866825 · 116 enrolled · Germany
- Nov 29, 2016Phase 2 study in Hidradenitis SuppurativaInflaRx · NCT03001622 · 12 enrolled · Greece
- Feb 27, 2018Phase 2 study in Hidradenitis SuppurativaInflaRx · NCT03487276 · 179 enrolled · United States, Bulgaria, Canada and more
- Oct 16, 2018Phase 2 study in Granulomatosis with PolyangiitisInflaRx · NCT03712345 · 20 enrolled · United States, Canada
- Mar 8, 2019Phase 2 study in Granulomatosis with PolyangiitisInflaRx · NCT03895801 · 57 enrolled · Belgium, Czechia, France and more
- May 28, 2019Phase 2 study in Pyoderma GangrenosumInflaRx · NCT03971643 · 19 enrolled · United States, Canada, Poland
- Apr 1, 2020Phase 3 study in Severe COVID-19 PneumoniaInflaRx · NCT04333420 · 399 enrolled · Belgium, Brazil, France and more
- Mar 10, 2021Phase 2 study in Neoplasm MetastasisInflaRx · NCT04812535 · 30 enrolled · United States, Belgium, France and more
- Jun 29, 2023Phase 3 study in Pyoderma GangrenosumInflaRx · NCT05964413 · 54 enrolled · United States, Australia, Belgium and more
- Nov 20, 2024PPD Development, LP's first studies: 2 phase 2 studies in Respiratory Distress SyndromeNew to PPD Development, LPPPD Development, LP · NCT06703073, NCT06701682
Ahead
- Jul 2028Primary completion: phase 2 study in Respiratory Distress SyndromePPD Development, LP · NCT06703073
- Jul 2028Primary completion: phase 2 study in Respiratory Distress SyndromePPD Development, LP · NCT06701682
TargetBeta
“A monoclonal antibody targeting the human complement factor C5a, ”NCIt, by rule
“Complement C5 inhibitor”ChEMBL 37, by rule
Other programs on C5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eculizumabrule | AstraZeneca | phase 4 | 38 |
| ravulizumabrule | AstraZeneca | phase 4 | 35 |
| pozelimabrule | Regeneron Pharmaceuticals | phase 4 | 14 |
| zilucoplanrule | UCB | phase 3 | 14 |
| Crovalimabrule | Hoffmann-La Roche | phase 3 | 10 |
| cemdisiranrule | Regeneron Pharmaceuticals | phase 3 | 10 |
| ABBV-6628 | AbbVie | phase 2 | 1 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06703073Respiratory Distress Syndrome · United States | 2 | Recruiting | PPD Development, LP | Jul 2028 | 600 |
| NCT06701682Respiratory Distress Syndrome · United States | 2 | Recruiting | PPD Development, LP | Jul 2028 | 200 |
| NCT05964413Pyoderma Gangrenosum · United States, Australia, Belgium and more | 3 | Terminated | InflaRx | Jul 11, 2025 | 54 |
| NCT04812535Neoplasm Metastasis · United States, Belgium, France and more | 2 | Terminated | InflaRx | Jun 4, 2024 | 30 |
| NCT04333420Severe COVID-19 Pneumonia · Belgium, Brazil, France and more | 3 | Completed | InflaRx | Oct 31, 2021 | 399 |
| NCT03971643Pyoderma Gangrenosum · United States, Canada, Poland | 2 | Completed | InflaRx | Jan 3, 2022 | 19 |
| NCT03895801Granulomatosis with Polyangiitis · Belgium, Czechia, France and more | 2 | Completed | InflaRx | Apr 14, 2021 | 57 |
| NCT03712345Granulomatosis with Polyangiitis · United States, Canada | 2 | Terminated | InflaRx | Sep 10, 2020 | 20 |
| NCT03487276Hidradenitis Suppurativa · United States, Bulgaria, Canada and more | 2 | Completed | InflaRx | May 27, 2019 | 179 |
| NCT03001622Hidradenitis Suppurativa · Greece | 2 | Completed | InflaRx | Jul 2017 | 12 |
| NCT02866825Systemic Inflammatory Response Syndrome · Germany | 2 | Completed | InflaRx | Dec 2016 | 116 |
| NCT02246595Sepsis · Germany | 2 | Completed | InflaRx | Dec 2015 | 72 |
| NCT01319903Sepsis · Germany | 1 | Completed | InflaRx | Oct 2011 | 26 |
How it is read
Names in the registry
- “IFX-1”, 4 entries
- “Cohort A: vilobelimab”, 2 entries
- “vilobelimab”, 2 entries
- “Vilobelimab”, 1 entry
- “Vilobelimab + pembrolizumab combination therapy”, 1 entry
Conditions, from the studies’ own filings
- Respiratory Distress Syndrome, 2 studies
- Pyoderma Gangrenosum, 2 studies
- Granulomatosis with Polyangiitis, 2 studies
- Hidradenitis Suppurativa, 2 studies
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.